CICLOSPORIN

Immunosuppressive medicine

Dosage Forms

Tablet

25 mg

Capsules

100 mg

Concentrate for intravenous infusion

50mg/ml

Uses

  • Prevention of graft rejection
  • Prophylaxis of graft-versus-host disease
  • Nephrotic syndrome
  • Inflammatory bowel disease
  • Rheumatoid arthritis
  • Psoriasis
  • Atopic dermatitis

Dose and Duration

Adjust dose according to plasma ciclosporin concentration and renal function. Lower doses are required when ciclosporin is used with other immunosuppressants
Organ transplantation
Adult and child over 3 months: by mouth, 10–15 mg/kg 4–12 hours before surgery given in 2 divided doses, then 10–15 mg/kg in 2 divided doses for 1–2 weeks and reducing it gradually to a maintenance dose of 2–6 mg/kg daily in 2 divided doses

By IV infusion: if using concentrated solution, give 1/3rd of the corresponding dose by mouth over 2–6 hours. Same dose as for oral administration when diluted

Bone marrow transplantation, graft-versus-host disease
Adult and child over 3 months:by mouth, 12.5–15 mg/kg daily in 2 divided doses for 2 weeks, starting on the day before surgery, followed by 12.5 mg/kg daily in 2 divided doses for 3–6 months, then gradually reduced to zero by 1 year after transplantation.

By IV infusion over 2–6 hours, 3–5 mg/kg daily for 2 weeks, starting on the day before surgery, followed by maintenance doses by mouth

Intractable hiccups
Adult:25–50 mg every 6–8 hours
Nephrotic syndrome
Adult:by mouth, initially 2.5 mg/kg every 12 hours slowly reduced to lowest effective dose according to proteinuria and serum creatinine measurements. Discontinue after 3 months if no improvement is observed (after 6 months in membranous glomerulonephritis)
Child:by mouth, initially 3 mg/kg every 12 hours and titrated as in the adult
Inflammatory bowel disease
Adult:by continuous IV infusion, 2 mg/kg daily over 24 hours adjusted according to blood ciclosporin concentration and response
Rheumatoid arthritis
Adult: 1.5 mg/kg every 12 hours for 6 weeks increased gradually according to response and tolerability up to a maximum 2.5 mg/kg every 12 hours for 6 more weeks
Psoriasis, atopic dermatitis
Adult: initially 1.25 mg/kg (2.5 mg/kg if rapid improvement is needed) every 12 hours gradually increased if there is no improvement after 1 month (2 weeks in dermatitis) to a maximum dose of 2.5 mg/kg every 12 hours. Treat for 8 weeks to 1 year in dermatitis Discontinue if there is no improvement after 6 weeks of treatment in psoriasis

Preparation

  • Dilute according to manufacturer’s directions

Contraindications

  • Porphyria
  • Malignancy
  • Uncontrolled infections

Side Effects

  • Nutrition disorders such as hyperlipidaemia, anorexia
  • Metabolism disorders e.g. hyperglycaemia, hyperuricaemia, hyperkalaemia and hypomagnesaemia
  • Leucopoenia
  • Tremor, paraesthesia, headache, convulsions, fever
  • Hypertension, flushing
  • Fatigue
  • Nausea, vomiting, abdominal pain, diarrhea
  • Gingival hyperplasia and peptic ulcer
  • Abnormal hepatic function
  • Hirsutism, acne, hypertrichosis (excessive body and/or facial hair growth)
  • Hirsutism, acne, hypertrichosis (excessive body and/or facial hair growth)
  • Renal dysfunction

Interactions

  • Amikacin, amphotericin B, ciprofloxacin, gentamicin, ibuprofen, levofloxacin, ofloxacin, silver sulfadiazine, streptomycin, sulfadiazine, sulfadoxine + pyrimethamine, vancomycin (increased risk of nephrotoxicity)
  • Silver sulfadiazine, sulfadiazine, sulfamethoxazole + trimethoprim, trimethoprim (plasma ciclosporin concentration possibly increased)
  • Amiloride (increased risk of hyperkalaemia)
  • Azithromycin, chloramphenicol, doxycycline, ritonavir (plasma concentration of ciclosporin possibly increased)
  • Carbamazepine, Phenobarbital, phenytoin, rifampicin ( reduced plasma ciclosporin concentration)
  • Chloroquine, erythromycin, fluconazole, grape fruit juice, levonogestrel, medroxyprogesterone, metoclopramide, norethisterone, verapamil (increased plasma concentration and toxicity of ciclosporin)
  • Oral contraceptives (Plasma ciclosporin concentration in creased)
  • Digoxin (increased concentration and toxicity of digoxin)
  • Doxorubicin (increased risk of neurotoxicity)
  • Enalapril, potassium salts, spironolactone (increased risk of hyperkalaemia)
  • Methotrexate (increased toxicity)
  • Simvastatin (increased risk of myopathy)

Pregnancy

  • Do not use

Breastfeeding

  • Do not use

⚠️ Caution

  • Monitor renal function. Reduce dose if dose-related in creases in serum creatinine and blood urea nitrogen oc cur during the first few weeks; exclude kidney transplant rejection
  • Monitor hepatic function. Adjust dose according to bilirubin and liver enzymes levels
  • Monitor blood pressure and discontinue if hypertension cannot be controlled by antihypertensives .
  • Monitor serum magnesium and potassium especially in renal impairment due to risk of hyperkalaemia
  • Monitor blood lipids before and during treatment
  • In patients with nephritic syndrome, reduce dose by 25-50% if serum creatinine is more than 30% above baseline at more than one measurement. Perform renal biopsies at yearly intervals
  • Monitor patients receiving the IV infusion for 30 minutes after starting the infusion since the polyethoxylated castor oil may cause anaphylaxis in some patients
  • When changing from IV to oral dose, start with similar dose as for IV and monitor ciclosporin plasma concentration for 4–7 days
  • Use in pregnancy may cause premature delivery